医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2014年
3期
95-95,96
,共2页
蔗糖铁%重组人红细胞生成素%血液透析%肾性贫血
蔗糖鐵%重組人紅細胞生成素%血液透析%腎性貧血
자당철%중조인홍세포생성소%혈액투석%신성빈혈
sucrose iron%Recombinant human erythropoietin%Hemodialysis%Renal anemia
目的:探究蔗糖铁联合大剂量EPO在肾性贫血患者中的应用价值。方法:随机选择在我院进行透析治疗的60例肾性贫血患者为观察对象,分为观察组及对照组,每组30例。观察组患者给予静脉补充蔗糖铁并联合大剂量EPO(重组人红细胞生成素)治疗,对照组则给予口服硫酸亚铁联合静脉EPO治疗。观察两组患者在治疗第4周的血红蛋白量(Hb)、红细胞压积(Hct)、红细胞胞(RBC)、血清铁蛋白(SF)及转铁蛋白饱和度(TSAT)等指标的变化。结果:观察组的血红蛋白量、红细胞压积、红细胞、血清铁蛋白及转铁蛋白饱和度的上升速度明显优于对照组,且均存在差异性,具有统计学意义(P<0.05)。结论:蔗糖铁联合大剂量EPO治疗血透患者肾性贫血的疗效确切,方便可行,不良反应发生率较低,是血液透析患者的有效理想补铁方案。
目的:探究蔗糖鐵聯閤大劑量EPO在腎性貧血患者中的應用價值。方法:隨機選擇在我院進行透析治療的60例腎性貧血患者為觀察對象,分為觀察組及對照組,每組30例。觀察組患者給予靜脈補充蔗糖鐵併聯閤大劑量EPO(重組人紅細胞生成素)治療,對照組則給予口服硫痠亞鐵聯閤靜脈EPO治療。觀察兩組患者在治療第4週的血紅蛋白量(Hb)、紅細胞壓積(Hct)、紅細胞胞(RBC)、血清鐵蛋白(SF)及轉鐵蛋白飽和度(TSAT)等指標的變化。結果:觀察組的血紅蛋白量、紅細胞壓積、紅細胞、血清鐵蛋白及轉鐵蛋白飽和度的上升速度明顯優于對照組,且均存在差異性,具有統計學意義(P<0.05)。結論:蔗糖鐵聯閤大劑量EPO治療血透患者腎性貧血的療效確切,方便可行,不良反應髮生率較低,是血液透析患者的有效理想補鐵方案。
목적:탐구자당철연합대제량EPO재신성빈혈환자중적응용개치。방법:수궤선택재아원진행투석치료적60례신성빈혈환자위관찰대상,분위관찰조급대조조,매조30례。관찰조환자급여정맥보충자당철병연합대제량EPO(중조인홍세포생성소)치료,대조조칙급여구복류산아철연합정맥EPO치료。관찰량조환자재치료제4주적혈홍단백량(Hb)、홍세포압적(Hct)、홍세포포(RBC)、혈청철단백(SF)급전철단백포화도(TSAT)등지표적변화。결과:관찰조적혈홍단백량、홍세포압적、홍세포、혈청철단백급전철단백포화도적상승속도명현우우대조조,차균존재차이성,구유통계학의의(P<0.05)。결론:자당철연합대제량EPO치료혈투환자신성빈혈적료효학절,방편가행,불량반응발생솔교저,시혈액투석환자적유효이상보철방안。
Objective: to explore the sucrose iron in combination with large dose of EPO application value in patients with renal anemia. Methods: randomly selected in our hospital for dialysis treatment of 60 patients with renal anemia as observation objects, divided into observation group and control group, 30 cases in each group. Observation group patients were given intravenous supplement iron sucrose and in combination with large dose of EPO (epoetin alfa) treatment, control group were given oral ferrous sulfate combined therapy with intravenous EPO. Observe two groups of patients in the treatment of 4 weeks the amount of hemoglobin (Hb), red blood cells deposited (Hct), RBC cell(RBC), serum ferritin (SF) and transferrin saturation (TSAT), and other indicators of change. Results: the observation group and the amount of hemoglobin, red blood cells deposited, erythrocyte, serum ferritin and transferrin saturation increase speed was better than control group, and there are differences, statistical y significant (P < 0.05). Conclusion: sucrose iron in combination with large dose of EPO treatment curative effect renal anemia in hemodialysis patients, convenient and feasible, the low incidence of adverse reactions, is an effective ideal of hemodialysis patients with iron.